Quia Pharma AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a QUIA.ST research report →
Companywww.quiapeg.com
QUIA PHARMA AB engages in the research, development, and commercialization of drug delivery system. Its product, Uni-Qleaver®, uses releasable pegylation technology that eliminates potential drawbacks and adjusts the drug's half-life. The company was founded by Marek Kwiatkowski and is headquartered in Uppsala, Sweden.
- CEO
- Richard Glimstedt
- IPO
- 2005
- Employees
- 3
- HQ
- Uppsala, SE
Price Chart
Valuation
- Market Cap
- $1.31M
- P/E
- -0.05
- P/S
- -1.38
- P/B
- 0.14
- EV/EBITDA
- -0.20
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 127.37%
- Op Margin
- 2024.00%
- Net Margin
- 2038.37%
- ROE
- -198.31%
- ROIC
- -297.19%
Growth & Income
- Revenue
- $460.00K · -89.48%
- Net Income
- $-28,929,000 · -75.08%
- EPS
- $-0.08 · 63.36%
- Op Income
- $-28,665,000
- FCF YoY
- 69.31%
Performance & Tape
- 52W High
- $0.03
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.56
- Avg Volume
- 32.63M
Get TickerSpark's AI analysis on QUIA.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our QUIA.ST Coverage
We haven't published any research on QUIA.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate QUIA.ST Report →